# Phase 3 thrombosis trials recruiting: 27 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 27 trials in phase 3 for thrombosis that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 thrombosis trials: 27 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/thrombosis

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 27
- Recruiting or not yet: 27
- Read on: November 19, 2026

## Trials

The 25 newest of 27, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 15, 2026 | NCT07875153 | Anticoagulant Cessation After Antiphospholipid Autoantibodies Loss in Thrombotic Antiphospholipid Syndrome | Assistance Publique - Hôpitaux de Paris | Phase 3 | Not yet recruiting | Antiphospholipid Syndrome, Thrombotic Antiphospholipid Syndrome, Thrombosis | 234 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07875153) |
| July 13, 2026 | NCT07697599 | Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted... | Regeneron Pharmaceuticals | Phase 3 | Recruiting | Venous Thromboembolism (VTE) | 1,908 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07697599) |
| June 4, 2026 | NCT07626411 | Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation | Regeneron Pharmaceuticals | Phase 3 | Recruiting | Atrial Fibrillation (AF) | 15,364 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07626411) |
| May 1, 2026 | NCT07560306 | \[64Cu\]FBP8 PET for Early Detection of Intracardiac Thrombus in Amyloid Cardiomyopathy | Brigham and Women's Hospital | Phase 3 | Recruiting | Cardiac Amyloidosis | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07560306) |
| April 6, 2026 | NCT07512960 | Duration of Dual Anti-Platelet Therapy in Chronic Limb Threatening Ischemia After Distal Revascularization | Fondation Hôpital Saint-Joseph | Phase 3 | Recruiting | CLTI Defined as Rutherford Category 4 or 5 | 614 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07512960) |
| March 25, 2026 | NCT07493304 | Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers | Regeneron Pharmaceuticals | Phase 3 | Recruiting | Venous Thromboembolism (VTE) | 1,600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07493304) |
| March 13, 2026 | NCT07471139 | SWITCH: Apixaban vs Vitamin K in HM3 | Columbia University | Phase 3 | Recruiting | LVAD (Left Ventricular Assist Device) Thrombosis, Heart Failure, Bleeding, Thrombosis; Artery, Stroke, Heart Transplant | 460 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07471139) |
| February 25, 2026 | NCT07432529 | Design and Rationale of the COLT Study | Azienda Sanitaria Locale ASL 6, Livorno | Phase 3 | Not yet recruiting | Venous Thrombosis Deep (Limbs), Post-thrombotic Syndrome, Venous Thromboembolism (VTE), Venous Insufficiency | 940 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07432529) |
| February 24, 2026 | NCT07430956 | Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable | Regeneron Pharmaceuticals | Phase 3 | Recruiting | Atrial Fibrillation (AF) | 2,628 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07430956) |
| February 13, 2026 | NCT07410117 | REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis | Regeneron Pharmaceuticals | Phase 3 | Recruiting | Cancer-Associated Thrombosis (CAT) | 1,120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07410117) |
| January 6, 2026 | NCT07318610 | Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease | Regeneron Pharmaceuticals | Phase 3 | Recruiting | Peripheral Artery Disease (PAD) | 7,050 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07318610) |
| October 9, 2025 | NCT07213778 | REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants | Regeneron Pharmaceuticals | Phase 3 | Recruiting | Symptomatic Venous Thromboembolism (VTE) | 2,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07213778) |
| April 13, 2025 | NCT06925698 | Immunosuppressive Therapy Alone Versus Plus Oral Anticoagulation in the Treatment of VT Associated With Behcet's Disease | Marmara University | Phase 3 | Not yet recruiting | Behcet Disease, Behcet Disease and Vascular Involvement, Deep Venous Thromboses, Post Thrombotic Syndrome | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06925698) |
| March 6, 2025 | NCT06861088 | The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer | Quercis Pharma AG | Phase 3 | Recruiting | Venous Thromboembolism, Metastatic Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma | 480 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06861088) |
| October 26, 2024 | NCT06658197 | Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke | Xuanwu Hospital, Beijing | Phase 3 | Recruiting | Stroke, Ischemic, Stroke, Acute, Thrombosis, Brain, Drug Effect | 850 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06658197) |
| September 24, 2024 | NCT06611319 | ENhanced Recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis After Primary Hip Arthroplasty | Sponsor not shown (see the record) | Phase 3 | Recruiting | Hip Arthroplasty, Total, Prevention of Venous Thromboembolism | 2,932 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06611319) |
| July 10, 2024 | NCT06494878 | The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity | University of Calgary | Phase 3 | Recruiting | Venous Thromboembolism, Postpartum Period, Aspirin, Low Molecular Weight Heparin | 8,805 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06494878) |
| May 1, 2024 | NCT06393868 | Reducing Gastrointestinal Bleeding With Proton Pump Inhibitor Therapy in Acute Venous Thromboembolism | Ottawa Hospital Research Institute | Phase 3 | Recruiting | Venous Thromboembolism, Gastro Intestinal Bleeding, Blood Clot | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06393868) |
| April 17, 2024 | NCT06370273 | Thromboprophylaxis in Lower Limb Immobilisation | Queen Mary University of London | Phase 3 | Recruiting | Thrombosis, Injury Leg | 10,044 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06370273) |
| January 8, 2024 | NCT06195540 | RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing | University Hospital, Angers | Phase 3 | Recruiting | Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism, Lower Limb Trauma, Thromboprophylaxis, Immobilisation | 1,424 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06195540) |
| December 1, 2023 | NCT06153394 | Prolonged Hypercoagulability Following Major Liver Resection for Malignancy | Western University, Canada | Phase 3 | Not yet recruiting | Hepatic Disease, Surgery-Complications, Hypercoagulability, Thrombosis | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06153394) |
| November 29, 2023 | NCT06149533 | Evaluate the Efficacy and Safety of Edoxaban on Prevention of Catheter-related Thrombosis (CRT) in Cancer Patients | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 3 | Not yet recruiting | Thrombosis, Venous, Cancer, Catheter Complications | 366 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06149533) |
| January 10, 2023 | NCT05679024 | Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation | Region Stockholm | Phase 3 | Recruiting | Chronic Kidney Diseases, Atrial Fibrillation, Stroke, Intracerebral Hemorrhage, Major Bleed, Cardiovascular... | 1,400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05679024) |
| November 25, 2022 | NCT05627375 | Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets | Centre Hospitalier Universitaire de Saint Etienne | Phase 3 | Recruiting | Venous Thromboembolic Disease | 1,400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05627375) |
| July 29, 2021 | NCT04981327 | The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis | University Hospital, Geneva | Phase 3 | Not yet recruiting | Deep Vein Thrombosis | 1,300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04981327) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 7 |
| Ottawa Hospital Research Institute | 2 |
| Fondation Hôpital Saint-Joseph | 1 |
| Xuanwu Hospital, Beijing | 1 |
| Western University, Canada | 1 |
| University of Calgary | 1 |
| Marmara University | 1 |
| Columbia University | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Sunnybrook Health Sciences Centre | 1 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 1 |
| University Hospital, Angers | 1 |
| Brigham and Women's Hospital | 1 |
| Quercis Pharma AG | 1 |
| Azienda Sanitaria Locale ASL 6, Livorno | 1 |
| University Hospital, Geneva | 1 |
| Centre Hospitalier Universitaire de Saint Etienne | 1 |
| Region Stockholm | 1 |
| Queen Mary University of London | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 9 |
| Canada | 7 |
| France | 6 |
| Japan | 4 |
| United Kingdom | 3 |
| China | 2 |
| Ireland | 2 |
| Georgia | 2 |
| Norway | 2 |
| Bulgaria | 1 |
| Romania | 1 |
| South Korea | 1 |
| Greece | 1 |
| Malaysia | 1 |
| Moldova | 1 |
| Spain | 1 |
| Belgium | 1 |
| Denmark | 1 |
| Netherlands | 1 |
| Poland | 1 |
| Turkey (Türkiye) | 1 |
| Austria | 1 |
| Germany | 1 |
| Finland | 1 |
| Iceland | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Water heater installers in the United States](https://specstream.ai/data/businesses/water-heater-installers/united-states)
- [Pediatric pulmonology practices in the United States](https://specstream.ai/data/businesses/pediatric-pulmonology-practices/united-states)
- [Graphic design firms in the United States](https://specstream.ai/data/businesses/graphic-design-firms/united-states)
- [Business financing companies in the United States](https://specstream.ai/data/businesses/business-financing-companies/united-states)
- [Tex-Mex restaurants in the United States](https://specstream.ai/data/businesses/tex-mex-restaurants/united-states)
- [Music schools in the United States](https://specstream.ai/data/businesses/music-schools/united-states)
